Ethylmorphine

Asthma, COPD, Chronic respiratory insufficiency

Ethylmorphine is contraindicated in patients with compromised respiratory function including asthma, COPD, and other conditions involving reduced baseline ventilatory capacity. The active metabolite morphine depresses brainstem respiratory centers in a dose-dependent manner, and impaired baseline respiratory reserve eliminates the safety margin between therapeutic and lethal respiratory depression.

Head injury, Raised intracranial pressure

Mu-opioid agonists including ethylmorphine are contraindicated in patients with head injuries or raised intracranial pressure. Opioid-induced miosis and sedation mask critical neurological signs used to monitor injury progression, while respiratory depression can elevate PaCO2, causing cerebral vasodilation and further intracranial pressure elevation.

Liver disease, Hepatic insufficiency

Pre-existing hepatic impairment is a relative contraindication due to ethylmorphine's dependence on hepatic CYP2D6 and CYP3A4 metabolism for both activation and elimination. Liver disease may unpredictably alter the morphine formation rate and parent drug clearance. Additionally, ethylmorphine depletes hepatic glutathione in mice (Skoulis et al. 1989), increasing vulnerability to co-administered hepatotoxins such as acetaminophen.

CYP2D6 ultrarapid metabolizer genotype

Individuals with CYP2D6 ultrarapid metabolizer genotype are at elevated risk of morphine toxicity from standard therapeutic doses of ethylmorphine. A dose in the 'common' range for an extensive metabolizer may produce 'strong' or higher equivalent morphine exposure in a UM individual. This relative contraindication is inferred from codeine pharmacogenomic safety data, where fatal outcomes in UM individuals are documented.

Children under approximately 8 years of age

Ethylmorphine is contraindicated in children under approximately 8 years of age. The risk is amplified in pediatric CYP2D6 ultrarapid metabolizers, who may convert ethylmorphine to morphine at rates producing supratherapeutic morphine concentrations. This risk pattern is established by fatal pediatric cases with codeine, ethylmorphine's closest structural analogue and fellow CYP2D6-dependent morphine prodrug.

Alcohol co-use, Benzodiazepine co-use, Barbiturate co-use, GHB/GBL co-use, Other opioid co-use

Combination with any CNS depressant — alcohol, benzodiazepines, barbiturates, GHB/GBL, or other opioids — is contraindicated due to additive respiratory depression. The ethanol–ethylmorphine interaction is particularly dangerous: ethanol inhibits O-deethylation by 44%, N-demethylation by 35%, and glucuronidation by 30–60% (Xu et al. 1997), creating a dual pharmacokinetic-pharmacodynamic lethal risk mechanism.

Intravenous administration of ethylmorphine is contraindicated due to the risk of dangerous histamine release. This contraindicates recreational IV use and limits clinical administration to oral and topical routes.

Paralytic ileus, Bowel obstruction

Ethylmorphine is contraindicated in patients with paralytic ileus or suspected bowel obstruction. The morphine metabolite activates enteric mu-opioid receptors, further suppressing gastrointestinal motility and potentially converting partial obstruction to complete obstruction.